Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer.

H H Hansen1, M Rørth

  • 1Department of Oncology, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.

Cancer Chemotherapy and Biological Response Modifiers
|May 9, 2000
PubMed
Summary
This summary is machine-generated.

Lung cancer treatment in 1997 saw modest gains. Combination chemotherapy with platin-compounds and podophyllotoxins remains standard for small cell lung cancer (SCLC), offering significant response rates but limited survival improvements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of alternative feed additives to medicinal zinc oxide on productivity, diarrhoea incidence and gut development in weaned piglets.

Animal : an international journal of animal bioscience·2020
Same author

Evaluation of the feeding value of Dichrostachys cinerea pods for fattening pigs in Cuba.

Tropical animal health and production·2017
Same author

High plasma triglyceride levels strongly correlate with low kisspeptin in the arcuate nucleus of male rats.

Endocrine regulations·2015
Same author

Technical note: In vitro total gas and methane production measurements from closed or vented rumen batch culture systems.

Journal of dairy science·2014
Same author

Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.

Developmental neuroscience·2010
Same author

The medullary nail presentation of a new type and report of a case.

Archives of surgery (Chicago, Ill. : 1920)·2010
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Area of Science:

  • Medical Oncology
  • Clinical Trials
  • Lung Cancer Therapeutics

Background:

  • Clinical trials in 1997 showed limited impact on lung cancer treatment outcomes.
  • Cytostatic agents and radiotherapy combinations yielded modest results.
  • Established chemotherapy regimens remain central to lung cancer management.

Purpose of the Study:

  • To review the impact of 1997 clinical trials on lung cancer treatment.
  • To assess current therapeutic strategies for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • To identify emerging treatments and areas needing further research.

Main Methods:

  • Review of clinical trial results published in 1997.
  • Analysis of treatment efficacy for SCLC and NSCLC.

Related Experiment Videos

  • Evaluation of response rates, survival data, and treatment durations.

    • Main Results:

    • In SCLC, combination chemotherapy with platin-compounds and podophyllotoxins is standard, achieving 80-90% response rates, 11-17 months median survival, and ~5% 5-year survival.
    • Treatment duration for SCLC has been reduced to 5-6 months.
    • Topotecan and paclitaxel show activity in relapsing SCLC.
    • Preoperative chemotherapy shows promise for Stage III NSCLC, but requires further study.
    • New platin-containing regimens for advanced NSCLC show 42-55% response rates in Phase II, necessitating Phase III validation.
    • No major advancements were noted for mesothelioma treatment.

    Conclusions:

    • Combination chemotherapy with platin-compounds and podophyllotoxins remains the cornerstone for SCLC.
    • Further research is needed for definitive recommendations on neoadjuvant chemotherapy in Stage III NSCLC.
    • Innovative treatments, particularly platin-based regimens with new agents, are crucial for advanced NSCLC management.
    • Significant improvements in mesothelioma therapy have not yet been achieved.